Carneiro Jaqueline, Gonçalves Alan, Zhou Zehua, Griffin Kaitlin E, Kaufman Nichole E M, Vicente Maria da Graça Henriques
Department of Pharmaceutical Sciences, Federal University of Paraná, Curitiba, Brazil.
Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana.
Lasers Surg Med. 2018 Jul;50(5):566-575. doi: 10.1002/lsm.22824. Epub 2018 Apr 25.
Photodynamic therapy (PDT) is an effective cancer treatment that uses photosensitizers, light, and oxygen to destroy malignant cells. Porphyrins, and in particular the cationic derivatives, are the most investigated photosensitizers for PDT. In this context, it is important to study new methodologies to develop efficient cationic photosensitizers for use in PDT.
New porphyrins bearing cationic epoxymethylaryl groups were synthesized and characterized. Their cellular uptake, intracellular localization, and phototoxicity were evaluated in human HEp2 cells, and compared with their methylated analogs.
All cationic porphyrins were efficient generators of singlet oxygen, with quantum yields in the range 0.35-0.61. The two methylated derivatives (3 and 4) accumulated the most within cells at all times investigated, up to 24 hours. Of these two porphyrins, 4 was the most phototoxic to the cells (LD = 2.4 μM at 1.5 J/cm ); however, porphyrin 3 also showed high phototoxicity (LD = 7.4 μM at 1.5 J/cm ). The epoxymethyl-containing porphyrins were found to be less phototoxic than the methylated derivatives, with LD > 38 μM. The neutral porphyrins showed no phototoxicity up to the 100 μM concentrations investigated, and had the lowest singlet oxygen quantum yields. All cationic porphyrins localized mainly in the cell ER, Golgi apparatus, and lysosomes.
Our results suggest that cationic methylated porphyrin derivatives are promising PDT photosensitizing agents. The epoxymethyl-containing derivatives showed increased efficacy relative to the neutral analogs, and are good candidates for further investigation. Lasers Surg. Med. 50:566-575, 2018. © 2018 Wiley Periodicals, Inc.
光动力疗法(PDT)是一种有效的癌症治疗方法,它利用光敏剂、光和氧气来破坏恶性细胞。卟啉,尤其是阳离子衍生物,是用于PDT研究最多的光敏剂。在此背景下,研究开发用于PDT的高效阳离子光敏剂的新方法很重要。
合成并表征了带有阳离子环氧甲基芳基的新型卟啉。在人HEp2细胞中评估了它们的细胞摄取、细胞内定位和光毒性,并与它们的甲基化类似物进行了比较。
所有阳离子卟啉都是单线态氧的有效产生剂,量子产率在0.35 - 0.61范围内。在所有研究的时间点(长达24小时),两种甲基化衍生物(3和4)在细胞内的积累量最大。在这两种卟啉中,4对细胞的光毒性最大(在1.5 J/cm²时LD₅₀ = 2.4 μM);然而,卟啉3也表现出高光毒性(在1.5 J/cm²时LD₅₀ = 7.4 μM)。发现含环氧甲基的卟啉的光毒性低于甲基化衍生物,LD₅₀ > 38 μM。在所研究的高达100 μM的浓度下,中性卟啉没有光毒性,并且单线态氧量子产率最低。所有阳离子卟啉主要定位于细胞内质网、高尔基体和溶酶体中。
我们的结果表明,阳离子甲基化卟啉衍生物是有前景的PDT光敏剂。含环氧甲基的衍生物相对于中性类似物显示出更高的疗效,是进一步研究的良好候选物。《激光外科与医学》50:566 - 575,2018年。© 2018威利期刊公司